Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02720679 · ClinicalTrials.gov registry record
Investigation of the Genetics of Hematologic Diseases
A clinical trial of Sickle Cell Disease and Diamond-Blackfan Anemia, sponsored by St. Jude Children's Research Hospital.
- Recruiting
- Registry status
- 1,716
- Enrollment target
- 1
- Study location
NCT02720679: Recruiting study of Sickle Cell Disease and Diamond-Blackfan Anemia, sponsored by St. Jude Children's Research Hospital.
NCT02720679 is a study of Sickle Cell Disease and Diamond-Blackfan Anemia that is actively recruiting participants, run by St. Jude Children's Research Hospital. The registered enrollment target is 1,716 participants, above the 285-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (502% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02720679, a study of Sickle Cell Disease and Diamond-Blackfan Anemia, is actively recruiting participants, sponsored by St. Jude Children's Research Hospital.
- RECRUITING
- Registry status
- 1,716 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to collect and store samples and health information for current and future research to learn more about the causes and treatment of blood diseases. This is not a therapeutic or diagnostic protocol for clinical purposes. Blood, bone marrow, hair follicles, nail clippings, urine, saliva and buccal swabs, left over tissue, as well as health information will be used to study and learn about blood diseases by using genetic and/or genomic research. In general, genetic research studies specific genes of an individual; genomic research studies the complete genetic makeup of an individual. It is not known why many people have blood diseases, because not all genes causing these diseases have been found. It is also not known why some people with the same disease are sicker than others, but this may be related to their genes. By studying the genomes in individuals with blood diseases and their family members, the investigators hope to learn more about how diseases develop and respond to treatment which may provide new and better ways to diagnose and treat blood diseases. Primary Objective: * Establish a repository of DNA and cryopreserved blood cells with linked clinical information from individuals with non-malignant blood diseases and biologically-related family members, in conjunction with the existing St. Jude biorepository, to conduct genomic and functional studies to facilitate secondary objectives. Secondary Objectives: * Utilize next generation genomic sequencing technologies to Identify novel genetic alternations that associate with disease status in individuals with unexplained non-malignant blood diseases. * Use genomic approaches to identify modifier genes in individuals with defined monogenic non-malignant blood diseases. * Use genomic approaches to identify genetic variants associated with treatment outcomes and toxicities for individuals with non-malignant blood disease. * Use single cell genomics, transcriptomics, proteomics and
Primary Outcome
It is estimated that approximately 30% of participants (proband) approached for this study will agree to participate and that each proband will have approximately five biologically-related family members who agree to participate.
Conditions Studied
Study Locations (1)
Tennessee
- St. Jude Children's Research Hospital - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,716 participants |
| Start Date | 2016-06-17 |
| Est. Completion | 2050-07 |
What NCT02720679 shows while recruiting
NCT02720679 is an observational study that tracks outcomes without assigning an intervention. Its 1,716 participants enrollment target places it among the larger protocols in the corpus, above the 285-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (502% higher).
The record links to 10 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 0 interventions.
NCT02720679 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT02720679 about?
NCT02720679 is a clinical study titled "Investigation of the Genetics of Hematologic Diseases". The purpose of this study is to collect and store samples and health information for current and future research to learn more about the causes and treatment of blood diseases. This is not a therapeutic or diagnostic protocol for clinical purposes. Blood, bone marrow, hair follicles, nail clippings,...
What is the current status of trial NCT02720679?
This trial is currently recruiting. The enrollment target is 1,716 participants. The study started on 2016-06-17. Estimated completion is 2050-07.
What conditions does trial NCT02720679 study?
This clinical trial studies the following conditions: Sickle Cell Disease, Diamond-Blackfan Anemia, Hemostasis, Dyskeratosis Congenita, Blood Coagulation Disorder.
Who is sponsoring clinical trial NCT02720679?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02720679 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02720679's enrollment target sits among peer trials
1,716 3rd of 213 higher than 211 of 213 other Sickle Cell Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
RECRUITING · Phase 2
-
Early Life Exposures Among Children With Sickle Cell Disease
RECRUITING · NA
-
Exercise in Child Health
RECRUITING · NA
-
Sickle Cell Children's Exercise Study (SuCCESs)
RECRUITING · NA
-
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
RECRUITING · Phase 1
-
Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04291612 · 1,715 participants
Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease
- NCT05303636 · 1,710 participants · Phase 4
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women
- NCT06898034 · 1,725 participants
Postpartum Ultrasound Evaluation to Assess Risk of Hemorrhage
- NCT07304531 · 1,705 participants
First To Know Pregnancy Test - Clinical Evaluation Protocol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI